Zelira in the news

Articles

For media related enquiries please contact Damien Carbon at Profile Media
Ph: +61 (0) 412 332 122 E: damienc@profilemedia.com.au

Hannam and Partners Investor Report – Zelira Therapeutics

Hannam and Partners investor report completed July 2022 provides an update and overview of Zelira Therapeutics following German regulatory approval and lists a target share price of $11.70.

Start typing and press Enter to search

Shopping Cart